Irhythm Technologies (IRTC)
NASDAQ:IRTC
Want to see IRTC full AI Analyst Report?
IRTC Stock Chart & Stats
$125.32
-$0.21(-0.23%)
At close: 4:00 PM EST
$125.32
-$0.21(-0.23%)
Day’s Range― - ―
52-Week Range$97.16 - $212.00
Previous CloseN/A
Volume94.23K
Average Volume (3M)492.27K
Market Cap
$4.02B
Enterprise Value$4.55B
Total Cash (Recent Filing)$583.76M
Total Debt (Recent Filing)$731.18M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Apr 30, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding32,316,760
10 Day Avg. Volume333,106
30 Day Avg. Volume492,272
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue6.08
Enterprise Value/Gross Profit8.62
Enterprise Value/Ebitda-577.60
Forecast
1Y Price Target
$189.40Price Target Upside51.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$876.19M
Bulls Say, Bears Say
Bulls Say
Financial StrengthAchievement of positive GAAP earnings per share and free cash flow signals improving profitability and greater financial flexibility to support growth without heavy reliance on external capital.
Product MomentumStrong demand for Zio AT and continued Zio Monitor sales, coupled with expanding adoption by innovative channel partners and international pilots, can drive sustained revenue growth and market share gains.
Reimbursement And Market AccessMedicare Advantage developments and pressure on CMS payments may push providers toward Zio's monitoring solutions to support auditable risk adjustment and cost-saving initiatives, aiding partnership opportunities and uptake.
Bears Say
Guidance And Valuation PressureFormal guidance that fell short of analyst expectations and valuation multiple compression across peers have triggered a lower price target and could sustain investor skepticism if revenue and margin improvements lag projections.
Product Launch DelayDelay in the commercial launch of the Zio MCT product lowers near-term revenue expectations and may slow anticipated contribution from the new product line.
Regulatory Investigation RiskReceipt of a civil investigative demand from the Department of Justice that targets reimbursement claims for Zio AT raises the potential for fines, settlements, or costly compliance actions that could negatively affect the stock.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $97.16 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $4.02B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Apr 30, 2026 which is in 11 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Feb 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.159.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.66.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,316,760 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of $0.17 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went down -4.985%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$189.40 (51.13% Upside)
$189.40 (51.13% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 480.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.67%
12-Months-Change
Fundamentals
Return on Equity
-38.33%
Trailing 12-Months
Asset Growth
9.51%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$189.40
▲(51.13% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---